Document Detail


Incidence and result of treatment-demanding retinopathy of prematurity using revised U.S. screening guidelines.
MedLine Citation:
PMID:  22773294     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To study the incidence of treated retinopathy of prematurity (ROP) using the revised U.S. screening guidelines, the rate of missed treatment, and unfavorable anatomic outcomes over a period of 2 years.
STUDY DESIGN: We reviewed the admission records of premature patients treated at our hospital from September 2008 to August 2010. Any baby born with a gestational age (GA) of less than 30 weeks or a birth body weight (BW) of less than 2000 g was included in this study. The ROP screening followed the revised U.S. screening guidelines as presented in 2006. The indications of treatment for ROP were threshold disease as defined by the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity study and type 1 prethreshold ROP as defined by the Early Treatment for Retinopathy of Prematurity Randomized Trial study.
RESULTS: There were 385 infants who were examined for ROP screening during this period. Nineteen babies (35 eyes) fit the treatment criteria and received treatment. The incidence of treatment-demand ROP was 4.9% (19/385). Four babies had a birth BW >1500 g (4/19; 21%). Seventeen babies received treatment during their first admission and two babies received treatment during outpatient follow-up. No baby missed timely treatment. Three eyes progressed to stage 4/5 after receiving intravitreal bevacizumab treatment. The success rate after primary bevacizumab was 91% (30/33 eyes).
CONCLUSION: The incidence of treatment-demanding ROP using revised U.S. screening criteria was 4.9%. Teamwork and cooperation are very important to ensure that the highest-quality care possible is provided to patients in a timely manner.
Authors:
Hsi-Kung Kuo; Chih-Cheng Chen; Yi-Hao Chen; Hsin-Chun Huang; Chieh-An Liu; Feng-Shun Chen; Mei-Yung Chung
Related Documents :
9252434 - Disappearing suprarenal masses in fetuses and infants.
12975784 - Pericardial teratoma complicated by hydrops: successful fetal therapy by thoracoamnioti...
22864004 - Transfusion-associated necrotizing enterocolitis: evidence and uncertainty.
25392604 - On the origins of disorganized attachment and internal working models: paper i. a dyadi...
24957344 - Neurodevelopmental outcomes of premature infants with bronchopulmonary dysplasia.
2116634 - Pregnancy and medical cost outcomes of a self-help prenatal smoking cessation program i...
Publication Detail:
Type:  Journal Article     Date:  2012-07-06
Journal Detail:
Title:  American journal of perinatology     Volume:  29     ISSN:  1098-8785     ISO Abbreviation:  Am J Perinatol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-05-24     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8405212     Medline TA:  Am J Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  827-31     Citation Subset:  IM    
Copyright Information:
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Affiliation:
Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Birth Weight
Early Medical Intervention* / methods,  statistics & numerical data
Female
Gestational Age
Hospitalization / statistics & numerical data
Humans
Incidence
Infant, Newborn
Infant, Premature
Intravitreal Injections
Male
Medical Records, Problem-Oriented
Multicenter Studies as Topic
Neonatal Screening / methods*,  organization & administration
Patient Selection
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Retinopathy of Prematurity* / diagnosis,  epidemiology,  physiopathology,  therapy
Severity of Illness Index
Taiwan / epidemiology
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does Delayed Pushing in the Second Stage of Labor Impact Perinatal Outcomes?
Next Document:  The effect of troglitazone on lipid accumulation and related gene expression in Hanwoo muscle satell...